Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

New Treatments May Help Those With Advanced Breast Cancer Live Longer

photo

SPONSORED CONTENT -- (StatePoint) As of January 2023, the number of women in the United States with a history of invasive breast cancer is estimated to be 3.1 million and is expected to increase by 12% to 4 million in 2024, according to the American Cancer Society.

Breast cancer is highly treatable when caught at the early stages -- there is a 99% five-year survival rate when the cancer is found only in the breast tissue. However, as soon as the cancer spreads to lymph nodes under the arm or to nearby tissues (regional stage), the 5-year survival rate drops to 85%, and once it spreads to other lymph nodes or body parts, (distant stage or metastatic cancer) the 5-year survival rate falls to as low as 27%. These figures suggest there is a significant need for more effective treatments for this deadly cancer.

New immunotherapies may provide the solution for patients with advanced breast cancer and fewer treatments options. Currently under development, Bria-IMT and Bria-OTS from BriaCell Therapeutics (NASDAQ: BCTX), are two drugs that have shown promising results so far in clinical trials, with substantial tumor regression in several patients, even those with metastatic cancer. Both drugs work through a completely novel therapeutic mechanism, using breast cancer cells to generate a strong immune response against breast cancer.

“For many breast cancer patients, the only option left is chemotherapy. We realize how hard chemotherapy is on the body, commonly causing nausea, vomiting, hair loss, lack of appetite, inflammation of the mouth and tongue, and bone marrow suppression, which can lead to serious and at times fatal infections. Recently, immunotherapies have come to the fore as a type of therapy which avoids most of these side effects. Unfortunately, immunotherapy only currently works in a small subset of patients, and then only when given with chemotherapy. We are dedicated to developing new, more effective immunotherapy approaches that have very few side effects and may provide substantial benefits to more patients. We hope our efforts will afford these patients another option that is much better tolerated and can provide improved quality of life and prolong their survival,” says Dr. William Williams, CEO of BriaCell Therapeutics.

In the case of Bria-OTS, a simple saliva test can determine a patient’s cell type so they can receive personalized immunotherapy treatment. Dr. Williams notes that this technology is already being explored for other cancer treatment uses, including prostate cancer, lung cancer, and melanoma. To learn more about the future of cancer treatment, visit briacell.com/about-briacell.

Breast cancer is the second leading cause of cancer death in U.S. women. Thankfully, drugs on the near horizon may transform the way we think about treating the disease, particularly in its later stages, and provide new hope to patients.

*****

Photo Credit: (c) KatarzynaBialasiewicz / iStock via Getty Images Plus

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.